2 transcripts
KPTI
Earnings call transcript
NASDAQ
2024 Q1
8 May 24
rapid deep and sustained reductions relative to baseline. Taken together, these data validate that the novel combination of selinexor plus ruxolitinib has
KPTI
Earnings call transcript
NASDAQ
2023 Q4
29 Feb 24
rapid, deep and sustained reductions relative to baseline. Taken together, data demonstrate that the novel combination of selinexor plus ruxolitinib
- Prev
- 1
- Next